(Q82014730)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

title

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

2

Caroline Staib

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

5

Volker Erfle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Kia Schulze

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Thomas Ebensen

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Carlos A Guzman

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

1 December 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

6678-6684

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: case report

14 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Evidence of airborne transmission of the severe acute respiratory syndrome virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

SARS: clinical features and diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Immunogenicity of SARS inactivated vaccine in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Protection of cats from infectious peritonitis by vaccination with a recombinant raccoon poxvirus expressing the nucleocapsid gene of feline infectious peritonitis virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Fibronectin-binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Polylactide-coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Cell type-specific cleavage of nucleocapsid protein by effector caspases during SARS coronavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Immunisation strategies for the management of severe acute respiratory syndrome (SARS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.006

7 January 2021

inferred from DOI database lookup

Dynamic changes of plasma cytokine levels in patients with severe acute respiratory syndrome

1 reference

12 December 2020

Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.

1 reference

12 December 2020

Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome

1 reference

12 December 2020

Live viral vectors: vaccinia virus

1 reference

12 December 2020

10.1016/J.VACCINE.2008.09.006

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18805454%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference